Adalimumab in Treating Refractory Livedoid Vasculopathy
Sign Up to like & getrecommendations! Published in 2022 at "Vaccines"
DOI: 10.3390/vaccines10040549
Abstract: Livedoid vasculopathy is a chronic, recurrent skin disorder. It seriously affects the quality of patients’ life. However, the pathogenesis has not been fully identified yet. Here, this retrospective study describes the successful use of anti-TNF-α… read more here.
Keywords: treating refractory; adalimumab treating; refractory livedoid; livedoid vasculopathy ... See more keywords